At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 121 enrolled
Drug / intervention
LIQ861 Inhaled Treprostinildrug
Likely dose
LIQ861 Inhaled Treprostinil 25 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
In Brief
A Phase 3 clinical trial evaluating LIQ861 Inhaled Treprostinil for Primary Pulmonary Hypertension. Completed, enrolled 121 participants across 38 sites.
Detailed Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Pulmonary Hypertension
CountriesUnited States
CollaboratorsNuventra, Inc.
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedJan 2018
Primary CompletionMay 2019
Study CompletionNov 2019
TodayJul 2026
First PostedJan 16, 2018
Enrollment StartJan 2, 2018
Primary CompletionMay 6, 2019
Study CompletionNov 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.5 years ago
Interventions
LIQ861 Inhaled Treprostinildrug
LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.